$3.2 million Placement to Advance Clinical Trials
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Patrys Limited has announced a successful placement to raise funds for advancing its clinical trials, securing commitments for a significant number of shares at a set price per share. The placement attracted strong demand from both new and existing investors, reflecting confidence in Patrys' focus on addressing unmet medical needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Patrys
- Investor Presentation - Broker Meets Biotech
- RLS-2201 Manufacturing and Regulatory Pathway Initiated
- Appendix 4D - Half Year Accounts - 31 December 2025
- Appointment of Chief Executive Officer
- Appendix 4C - Quarterly - 31 December 2025
Later from Patrys
- Appendix 4C - Quarterly - 31 March 2026
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Patrys Secures 50% Revenue Share in IP Commercialisation
- Appendix 4C - Quarterly - 30 June 2026
- Investor Presentation - TechKnow Invest Roadshow
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys